Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

BACKGROUND: Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic disease-modify...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Burkhardt, Harald, Feist, Eugen, Krüger, Klaus, Rech, Juergen, Rubbert-Roth, Andrea, Voll, Reinhard E., Elbez, Yedid, Rauch, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795278/
https://www.ncbi.nlm.nih.gov/pubmed/29329602
http://dx.doi.org/10.1186/s13075-017-1488-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795278/
https://www.ncbi.nlm.nih.gov/pubmed/29329602
http://dx.doi.org/10.1186/s13075-017-1488-5

Ejemplares similares